Daiichi Sankyo in UK

A long-term and committed investor in the UK

We are a pharmaceutical company with 17,000 people in more than 20 countries. There are 240 people at Daiichi Sankyo in the UK, 75% of whom are customer facing*.

Between 2017-19, Daiichi Sankyo funded UK-based research as part of 10 multi-centre trials (randomised controlled trials, real-world evidence and registries) across our cardiovascular disease (CVD) portfolio. 

This equates to a total investment of more than €13 million into UK-based research, demonstrating our commitment to the UK.

Working with the National Health Service (NHS)

At Daiichi Sankyo UK, the National Health Service is our biggest stakeholder. That’s why we make it our business to understand the challenges faced by the four devolved nations. Variations in policy and funding are often determined by disease morbidity and mortality rates. In the south of England, for example, early deaths arising from CVD are lower than in other UK regions**.

Regional guidance from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium and Scottish Intercollegiate Guidelines Network, and the All Wales Strategy Group has significant influence on prescribing and patient care.

Whilst we adapt our programmes to reflect the wider goals of the NHS, such as reducing the impact of CVD and diabetes, we also tailor our service to meet the local needs of our customers. This collaborative approach between the NHS and industry, supported by the Department of Health and the ABPI, enables pioneering treatments and models of care to be developed and delivered direct to patients.

*Daiichi Sankyo UK company data.
**British Heart Foundation. Heart Statistics. BHF Statistics Factsheet – UK. January 2022. Available at: https://www.bhf.org.uk/what-we-do/our-research/heart-statistics Last accessed March 2022.

Our customer focus

To meet the needs of the evolving NHS, commercial operations at Daiichi Sankyo UK are structured into regional business units. We maintain our competitive edge by deploying our people and resources appropriately across the country, according to local or individual requirements.

We work with prescribing advisors, GPs, nurses, dispensing managers, practice managers and retail pharmacists in primary care – through to consultants, hospital doctors, nurses, business managers and pharmacists in secondary care.

With such a diverse range of customers, we train our people to the highest level to provide quality advice and information on all our products.

Highly-skilled medical liaison and medical services teams complement our sales and marketing specialists by providing essential clinical, scientific, pharmacovigilance and regulatory support to our UK customers.




As a company we work to support physicians and the wider healthcare system in tackling the great healthcare challenges of our time. This includes providing solutions to policy, commissioning and service delivery challenges in the NHS. In this section you will find published reports on policy, public affairs and campaigns which we support in cardiovascular disease and oncology.

Report: Closing the cholesterol gap (May 2022)

Report: Secondary breast cancer and COVID19 recovery plan (October 2021)


DSC/22/0110 June 2022



back to top